2 Information about avatrombopag and lusutrombopag
2.1 Avatrombopag (Doptelet, Dova Pharmaceuticals): On 26 April 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for avatrombopag 'for the treatment of the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure'.
2.2 Lusutrombopag (Mulpleo, Shionogi B.V.): On 14 December 2018, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for lusutrombopag 'for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures'.
2.3 The recommended dosage of avatrombopag is based on the patient's platelet count:
below 40,000 platelets per microlitre of blood – 60 mg once daily
40,000 to 50,000 platelets per microlitre of blood – 40 mg once daily.
Dosing should begin 10 to 13 days before the planned procedure. Patients should have their procedure 5 to 8 days after the last dose of avatrombopag. Avatrombopag is taken orally.
2.4 The recommended dosage of lusutrombopag is 3 mg once daily for 7 days. The procedure should be done from day 9 after the start of lusutrombopag treatment. Platelet count should be measured before the procedure. Lusutrombopag is taken orally.